慢行乙型病毒性肝炎治疗药物的经济学评价

目的：慢性HBV的抗病毒药物治疗已经取得突破性进展，但我国相关的医疗保险政策和治疗药物品种遴选严重滞后。本文用药物经济学评价慢性HBV治疗中基本医疗保险政策和药品目录遴选，以期为合理的基本医疗保险费用、药物治疗品种选择等提供依据。方法：针对慢性HBV治疗现状，分析我国基本医疗保险制度存在的问题，用药物经济学方法评价和遴选基本医疗保险用药品种，制定医院临床用药目录和治疗方案，评价单病种治疗药物和方案，指导公众选择药物。结果：开展慢行乙型病毒性肝炎治疗药物的经济学研究和评价，有利于为患者选择合理的药物治疗方案，有助于有限的医疗保险基金发挥最大效益。结论：药物经济学是研究和解决合理的基本医疗保险费用、药物治疗品种选择、临床合理用药等问题的重要工具，是解决基本医疗保险费用和药物治疗品种选择的重要手段。

Pharmacoeconomic Evaluation on Therapeutic Drugs for Chronic Viral Hepatitis Type B

OBJECTIVE： A breakthrough has been made in the treatment of chronic hepatitis B virus （HBV） using antiviral drugs; however, the related medical insurance policy in China and the selection of drugs for the treatment of HBV lag far behind. This paper aimed to evaluate the basic medical insurance policy in China and the selection of drug list for the treatment of chronic HBV so as to provide references for the rational basic medical insurance expense and the selection of drug variety etc. METHODS： In view of the status quo of treating chronic HBV, we analyzed the problems encountered in the basic medical insurance system in our country, applied the pharmacoeconomic method to evaluate and select the drug varieties to be covered by basic medical insurance, formulated the drug list and treatment plan in hospital, evaluated the drugs and the therapeutic scheme for one kind of disease and offered guidance in drug selection for public. RESULTS： The pharmacoeconomic study and evaluation on drugs for chronic HBV can help choose rational therapeutic schemes for patients and maximize the efficiency of the limited medical insurance fund. CONCLUSION： Pharmacoeconomics is an important tool for the study and solution of issues including rational basic medical insurance expense, selection of drug variety and clinical. rational drug use as well as an important means in dealing with the problems of basic medical expense and selection of drug variety.